News - TP53 expression

FKBP4 promotes glycolysis and hepatocellular carcinoma progression via p53/HK2 axis. (PubMed, Sci Rep)

Our study elucidates a novel role of FKBP4 in promoting HCC development and glycolysis by modulating the p53/HK2 signaling pathway. Given the critical role of aerobic glycolysis in the progression of HCC, targeting FKBP4 may offer a new therapeutic strategy for treating this malignancy.

4 days ago

Journal

FKBP5 (FKBP Prolyl Isomerase 5)

TP53 expression

Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors. (PubMed, Eur Urol Open Sci)

We previously developed and validated a signature reflecting low TSG expression (TSGlow) that was associated with poor outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) ± docetaxel...We found that patients with low expression of two out of three tumor suppressor genes (TP53, RB1, PTEN) had worse clinical outcomes and had aggressive variants of prostate cancer. Measuring the expression of these genes in early-stage prostate cancer could help in finding better treatments for these patients.

8 days ago

Journal • Metastases

TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1)

TP53 expression

docetaxel

Protective Effect of Biochanin A on Gamma Radiation-Induced Oxidative Stress, Antioxidant Status, Apoptotic, and DNA Repairing Molecules in Swiss Albino Mice. (PubMed, Cell Biochem Funct)

In conclusion, BCA demonstrates promising radioprotective properties by attenuating oxidative stress, enhancing antioxidant defences, modulating apoptotic pathways, and promoting DNA repair mechanisms following gamma radiation exposure. Further research is necessary to elucidate its precise mechanisms of action and explore its potential therapeutic applications in radiation oncology and environmental radioprotection.

9 days ago

Preclinical • Journal • IO biomarker

TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • GADD45A (Growth arrest and DNA-damage-inducible, alpha) • CAT (Catalase)

TP53 expression

10d

Effect of Different Concentrations of PRP on the Expression of Factors Involved in the Endometrial Receptivity in the Human Endometrial Cells from RIF Patients Compared to the Controls. (PubMed, Reprod Sci)

Moreover, protein expression of COX2/b, LIF/b and p53/b increased following treatment with PRP in the RIF group with the endometrium thickness < 7 mm. PRP enhances expression of LIF, COX2, p53, ERs and PRs in the RIF patients with thin endometrium which may improve endometrium receptivity.

10 days ago

Journal

ER (Estrogen receptor) • PGR (Progesterone receptor) • MT-CO2 (Mitochondrially Encoded Cytochrome C Oxidase II) • LIF (LIF Interleukin 6 Family Cytokine)

TP53 expression • PTGS2 expression

10d

Versatile properties of Opuntia ficus-indica (L.) Mill. flowers: In vitro exploration of antioxidant, antimicrobial, and anticancer activities, network pharmacology analysis, and In-silico molecular docking simulation. (PubMed, PLoS One)

More investigations might be required to test the mechanistic pathways by which O. ficus-indica (L.) Mill. might exhibit its biological activities in vivo.

10 days ago

Preclinical • Journal

TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • CASP3 (Caspase 3)

CCND1 expression • TP53 expression

10d

Salubrious effects of proanthocyanidins on behavioral phenotypes and DNA repair deficiency in the BTBR mouse model of autism. (PubMed, Saudi Pharm J)

In addition, proanthocyanidins reduced the elevated oxidative stress and recovered the disrupted DNA repair mechanism in the autistic animals by decreasing the expressions of Gadd45a and Parp1 levels and enhancing the expressions of Ogg1, P53, and Xrcc1 genes. This indicates that proanthocyanidins have significant potential as a new therapeutic strategy for alleviating autistic features.

10 days ago

Preclinical • Journal • PARP Biomarker

TP53 (Tumor protein P53) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • OGG1 (8-Oxoguanine DNA glycosylase) • DRD (DNA Repair Deficiency) • XRCC1 (X-Ray Repair Cross Complementing 1)

DDR • TP53 expression • DRD

10d

Biosynthesis of Copper Oxide-Silver Nanoparticles from Ephedra Intermedia Extract and Study of Anticancer Effects in HepG2 Cell Line: Apoptosis-Related Genes Analysis and Nitric Oxide Level Investigations. (PubMed, Int J Mol Cell Med)

Additionally, the presence of Ag-doped CuO NPs significantly increased NO activity enzyme and ROS generation compared to the plant extract. The biosynthesized Ag-doped CuO NPs demonstrated the ability to induce apoptosis, increase ROS production, and enhance NO enzyme activity in HepG2 cancer cells, suggesting their potential as a therapeutic agent for liver cancer.

10 days ago

Preclinical • Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)

TP53 expression • BAX expression

11d

Elucidating the anticancerous efficacy of genistein via modulating HPV (E7 and E6) oncogenes expression and apoptotic induction in cervical cancer cells. (PubMed, Biotechnol Appl Biochem)

Consequently, our data suggests that genistein could be a powerful candidate for treating cervical cancer by targeting two important oncogenes involved in viral development. However, more in vitro research on primary cervical cancer cells is required to validate the clinically relevant efficacy of genistein against cervical cancer.

11 days ago

Journal

TP53 (Tumor protein P53)

TP53 expression

11d

Association between the levels of toxic heavy metals and schizophrenia in the population of Guangxi, China: A Case-Control Study. (PubMed, Environ Pollut)

Elevated levels of tumor necrosis factor (TNF) and interleukin-1 beta (IL-1β) were observed in patients with schizophrenia, while the expression of tumor protein p53 (TP53) was significantly reduced. These findings underscore the critical need to avoid exposure to toxic heavy metals to prevent schizophrenia, highlighting significant public health implications.

11 days ago

Journal

TP53 (Tumor protein P53) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)

TP53 expression

11d

PPM1D/Wip1 is amplified, overexpressed, and mutated in human non-Hodgkin's lymphomas. (PubMed, Mol Biol Rep)

We found that PPM1D gained gene copy number in NHL tumors by 0.7-8 times compared to the control (p < 0.01). Increased PPM1D/Wip1 gene copy number was associated with higher mRNA and protein expression in human NHL samples (p < 0.01). Overexpression of Wip1 in NHL tumors and NHL cell lines was associated with amplification level and was unaffected by p53 status. Furthermore, a heterozygous type insertion mutation was detected in exon 6 (c.1553_1554insA) of the PPM1D gene particularly in DLBCL samples. Wip1 may have oncogenic potential, perhaps playing a role in the onset and progression of human NHL. The possible significance of Wip1 overexpression to chemotherapy response in NHL remains an intriguing question that requires more exploration.

11 days ago

Journal

TP53 (Tumor protein P53) • PPM1D (Protein Phosphatase Mg2+/Mn2+ Dependent 1D)

TP53 expression • PPM1D mutation

11d

Design, synthesis, and in vitro and in vivo biological evaluation of dihydroartemisinin derivatives as potent anti-cancer agents with ferroptosis-inducing and apoptosis-activating properties. (PubMed, Eur J Med Chem)

In an HCT-116 xenograft mouse model, compound A3 exhibited significant anti-cancer efficacy, with a tumor growth inhibition rate of 58.7 %. Therefore, compound A3 thus has the potential to serve as a lead compound for the development of new anti-tumor drugs.

11 days ago

Preclinical • Journal

TP53 (Tumor protein P53) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • GPX4 (Glutathione Peroxidase 4) • PI3K (Phosphoinositide 3-kinases)

TP53 expression

12d

Xenotropic and polytropic retrovirus receptor 1 (XPR1) promotes progression of papillary thyroid carcinoma via the BRAF-ERK1/2-P53 signaling pathway. (PubMed, J Endocrinol Invest)

The findings reveal a crucial role of XPR1 in PTC progression and prognosis via the BRAF-ERK1/2-P53 signaling pathway, providing potential therapeutic targets for treating PTC.

12 days ago

Journal

BRAF (B-raf proto-oncogene)

TP53 expression

12d

Shenqifuzheng injection inhibits lactic acid-induced cisplatin resistance in NSCLC by affecting FBXO22/p53 axis through FOXO3. (PubMed, Respir Res)

SQFZ influences LA-induced DDP resistance in NSCLC via FOXO3/FBXO22/p53 pathway, providing a promising agent for NSCLC treatment.

12 days ago

Journal

FOXO3 (Forkhead box O3)

TP53 expression

cisplatin

13d

Clinicopathological correlations in 38 cases of gastroenteropancreatic high-grade neuroendocrine neoplasms. (PubMed, Front Oncol)

Furthermore, ROC curve analysis highlighted the diagnostic significance of the positive expression of the immunohistochemical markers CLU, SSTR2, and RB in identifying NET G3. To guide more suitable treatment strategies, it is essential to develop and apply valuable and more targeted immunohistochemical and molecular pathological markers for a comprehensive analysis.

13 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • CLU (Clusterin) • MKI67 (Marker of proliferation Ki-67)

BRAF V600E • BRAF V600 • TP53 expression

13d

Phase I First-in-Human Dose Escalation Study of the oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 inhibitor BTX-A51 in advanced MDS and AML. (PubMed, Res Sq)

Ex-vivo studies confirmed higher efficacy of BTX-A51 on RUNX1 -mutated myeloblasts and demonstrate synergy with azacitidine and venetoclax. Although the overall efficacy was modest, this study lays the groundwork for future studies with improved patient selection and combination approaches.

13 days ago

P1 data • Journal • Metastases

RUNX1 (RUNX Family Transcription Factor 1) • CDK7 (Cyclin Dependent Kinase 7)

RUNX1 mutation • MCL1 expression • TP53 expression

Venclexta (venetoclax) • azacitidine • BTX-A51

14d

Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer (clinicaltrials.gov)

P=N/A, N=120, Not yet recruiting, Galzu Institute of Research, Teaching, Science and Applied Technology | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Sep 2024 --> Jun 2025

14 days ago

Trial completion date • Trial primary completion date

TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • S100P (S100 calcium binding protein P)

BRCA1 mutation • ATM mutation • TP53 expression

14d

Polo-like kinase 2 targeting as novel strategy to sensitize mutant p53-expressing tumor cells to anticancer treatments. (PubMed, J Mol Med (Berl))

Polo-like kinase 2 (PLK2) binds and phosphorylates mutant p53 protein strengthening its GOF activities. Pharmacologically targeting PLK2 weakens mutant p53 proteins and sensitizes tumor cells to therapeutic treatments.

14 days ago

Journal • Tumor cell

TP53 (Tumor protein P53) • PLK2 (Polo Like Kinase 2)

TP53 mutation • TP53 expression

15d

Comprehensive Clinicopathological and Immunohistochemical Analysis of Human Papillomavirus-independent Squamous Cell Carcinoma and Adenosquamous Carcinoma of the Uterine Cervix. (PubMed, Anticancer Res)

HPVI SCC is a rare and aggressive cervical malignancy that presents initially as advanced-stage disease with poor prognosis. Although the patients with initial stage I and II HPVI ASC were treated with curative intent, distant metastases appeared in the lungs during the early course of treatment. Further investigations are necessary to clarify the association between histological features and clinical behavior of HPVI ASC.

15 days ago

Journal

TP53 (Tumor protein P53)

TP53 expression

16d

A retrospective study on the prognosis of endoscopic surgery for 385 early glottic cancer patients (PubMed, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi)

Endoscopic surgery for early glottic carcinoma yields favorable short-term OS and reduces short-term recurrence rates, with T-stage emerging as a pivotal factor influencing recurrence. Tumors with poor differentiation and elevated expression of P53 may be indicative of an increased risk of recurrence.

16 days ago

Retrospective data • Journal • Surgery

TP53 (Tumor protein P53)

TP53 expression

16d

Loss of myosin light chain kinase induces the cellular senescence associated secretory phenotype to promote breast epithelial cell migration. (PubMed, Sci Rep)

Subsequently, p21Cip1 promotes the secretion of soluble ICAM-1, IL-1α, IL-6 and IL-8, thereby enhancing collective cell migration in a non-cell-autonomous manner. These findings provide new mechanistic insights into the role of MLCK in cellular senescence and cancer progression.

16 days ago

Journal

TP53 (Tumor protein P53) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • ICAM1 (Intercellular adhesion molecule 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • MYLK (Myosin Light Chain Kinase)

TP53 expression

19d

Biomarker Profiles and Clinicopathological Features in Head and Neck Squamous Cell Carcinoma Patients. (PubMed, Medicina (Kaunas))

Women may develop more aggressive tumors, and extralaryngeal tumors often present with more challenging prognoses. Low Cx43 expression may be more likely to coincide with higher Ki67 and COX-2 levels, possibly indicating a link with more aggressive tumor behavior.

19 days ago

Journal

EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • GJA1 (Gap Junction Protein Alpha 1)

TP53 mutation • EGFR expression • TP53 expression • GJA1 expression

19d

Apigenin Ameliorates H2O2-Induced Oxidative Damage in Melanocytes through Nuclear Factor-E2-Related Factor 2 (Nrf2) and Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase B (Akt)/Mammalian Target of Rapamycin (mTOR) Pathways and Reducing the Generation of Reactive Oxygen Species (ROS) in Zebrafish. (PubMed, Pharmaceuticals (Basel))

Apigenin promotes the expression of melanocyte autophagy-related proteins and the key mitochondrial autophagy proteins BNIP3L/Nix under oxidative stress, and activates the PINK1/Parkin signaling pathway by up-regulating the expression of autophagy-related proteins, as well as the expression of PINK1 and Parkin proteins, to promote melanocyte autophagy and mitochondrial autophagy. Apigenin exerts anti-melanocyte premature aging and detachment effects by promoting melanin synthesis, autophagy, and mitochondrial autophagy in melanocytes, and inhibiting oxidative cell damage and senescence.

19 days ago

Journal

AKT1 (V-akt murine thymoma viral oncogene homolog 1) • mTOR (Mechanistic target of rapamycin kinase) • BNIP3L (BCL2 Interacting Protein 3 Like) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • PI3K (Phosphoinositide 3-kinases) • PINK1 (PTEN Induced Kinase 1)

TP53 expression

19d

Hepatitis B Virus X Protein Induces Reactive Oxygen Species Generation via Activation of p53 in Human Hepatoma Cells. (PubMed, Biomolecules)

Additionally, HBx variants with Ser-101 increased p53 and ROS levels, whereas variants with Pro-101 did not. These dual mechanisms of HBx-induced ROS generation are likely significant in the pathogenesis of HBV and may contribute to liver diseases, including hepatocellular carcinoma.

19 days ago

Journal

CAT (Catalase)

TP53 expression • TP53 amplification

19d

Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia. (PubMed, Leukemia)

Of additional interest, CLL with aberrant BCAT1 expression were less sensitive to Venetoclax-induced apoptosis. Biologically, three CLL-derived cell lines with disruption of BCAT1 had substantially reduced growth ex vivo. Clinically, the expression of any detectable BCAT1 protein in CLL independently associated with shorter median survival (125 months versus 296 months; p < 0.0001), even after exclusion of del17p/TP53mut cases.

19 days ago

Journal

BCAT1 (Branched Chain Amino Acid Transaminase 1 )

TP53 expression • BCAT1 expression • TS 12

Venclexta (venetoclax)

19d

Circadian rhythm genes contribute to the prognosis prediction and potential therapeutic target in gastric cancer. (PubMed, Sci Rep)

Additionally, gastric cancer tissues exhibited elevated expression of OPN3 and decreased expression of TP53 compared to adjacent tissue. This study successfully established a prognostic signature for CRGs, accurately predicting prognosis and immunotherapeutic response among STAD patients, providing insights for the development of personalized therapeutic strategies for these patients.

19 days ago

Journal • IO biomarker

TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8)

TP53 expression

20d

SHARPIN is a novel gene of colorectal cancer that promotes tumor growth potentially via inhibition of p53 expression. (PubMed, Int J Oncol)

Furthermore, SHARPIN was found to be overexpressed in several cancer types, exerting significant effects on survival outcomes. In conclusion, SHARPIN represents a newly identified novel gene with the potential to promote tumor growth following apoptosis inhibition and cell cycle progression in part by inhibiting p53 expression via MDM2 upregulation; therefore, SHARPIN represents a potential therapeutic target for CRC.

20 days ago

Journal

MDM2 (E3 ubiquitin protein ligase)

TP53 expression

21d

Key Genes Involved in the Beneficial Mechanism of Hyperbaric Oxygen for Glioblastoma and Predictive Indicators of Hyperbaric Oxygen Prolonging Survival in Glioblastoma Patients. (PubMed, Curr Med Sci)

HBO is beneficial for glioblastoma. Glioblastoma patients with these predictive indicators may prolong survival with HBO therapy. These potential therapeutic targets especially COL1A1, ADAMTS1 and PTBP3 deserve further validation.

21 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

NF1 (Neurofibromin 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • PD-1 (Programmed cell death 1) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • MDM4 (The mouse double minute 4) • CDK6 (Cyclin-dependent kinase 6) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CA9 (Carbonic anhydrase 9) • COL1A1 (Collagen Type I Alpha 1 Chain) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen) • ADAMTS1 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 1) • CDC42 (Cell Division Cycle 42) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • DDIT3 (DNA-damage-inducible transcript 3) • IGFBP3 (Insulin-like growth factor binding protein 3) • IGFBP5 (Insulin Like Growth Factor Binding Protein 5) • BAK1 (BCL2 Antagonist/Killer 1) • CDC25A (Cell Division Cycle 25A) • COL12A1 (Collagen Type XII Alpha 1 Chain) • COL8A1 (Collagen Type VIII Alpha 1 Chain) • EFEMP1 (EGF Containing Fibulin Extracellular Matrix Protein 1) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • MCM2 (Minichromosome maintenance complex component 2) • RHOJ (Ras Homolog Family Member J) • NLRP2 (NLR Family Pyrin Domain Containing 2)

TP53 expression • CXCL12 expression • CDK6 expression • CDKN1B expression • PCNA expression

22d

Cheminformatics-aided discovery of potential allosteric site modulators of ubiquitin-specific protease 7. (PubMed, Sci Rep)

Also, molecular dynamics simulation confirmed the stability of the protein-ligand complexes. Conclusively, the compounds identified in this study are worthy of further evaluation for the development of allosteric site modulators of USP7.

22 days ago

Journal

TP53 (Tumor protein P53) • USP7 (Ubiquitin Specific Peptidase 7)

TP53 expression • MDM2 overexpression

22d

TFE3 and TP53 were novel diagnostic biomarkers related to mitochondrial autophagy in chronic rhinosinusitis with nasal polyps. (PubMed, Front Genet)

The drugs (Doxorubicin, Tetrachlorodibenzodioxin, etc.) and the ear-nose-throat diseases (hearing loss, sensorineural, tinnitus, etc.) related to biomarkers were predicted. Ultimately, qPCR results showed that the expression levels of TFE3 and TP53 in polyp tissue of CRSwNP were increased. Overall, TFE3 and TP53 could be used as biomarkers or potential therapeutic targets to diagnose and treat CRSwNP.

22 days ago

Journal

TP53 (Tumor protein P53) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3)

TP53 expression

doxorubicin hydrochloride

23d

High prevalence of chromosome 17 in breast cancer micronuclei: a means to get rid of tumor suppressors? (PubMed, Hum Cell)

The high prevalence of chromosome 17 in BC MN may connote the importance of its rearrangements in the pathogenesis of BC. Further, the higher prevalence of chromosome 17 and 1 signals in TNBC MN point towards the significance of pathogenetic events involving the genes located in these chromosomes in evolution of this more aggressive phenotype.

23 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53)

EGFR positive • TP53 expression

23d

Lower expressions of MIR34A and MIR31 in colo-rectal cancer are associated with an enriched immune microenvironment. (PubMed, Pathol Res Pract)

Lower MIR34A and MIR31 levels are associated with higher TILs density in CRC. Unlike other cancers where MIR34A has anti-tumour effects, there was no statistically significant correlation between its expression and the pT or TNM stages in this study. Increased TILs being a good prognostic indicator, this suggests MIR34A and MIR31 may help CRC cells evade immune surveillance. Aberrant p53 expression downregulates MIR34A, underscoring the therapeutic potential of miRs.

23 days ago

Journal

TP53 (Tumor protein P53) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • MIR31 (MicroRNA 31)

TP53 expression • CTNNB1 expression • miR-34a expression • miR-34a underexpression

24d

Identification of new leads against ubiquitin specific protease-7 (USP7): a step towards the potential treatment of cancers. (PubMed, RSC Adv)

Four compounds i.e., 4-hydroxy-diphenyl amine (2), phenyl-(2,3,4-trihydroxyphenyl) methanone (3), 4'-amino-2',5'-diethoxy benzanilide (5), and hydroquinone (12), showed anti-cancer activity against colorectal cancerous cells (HCT116) with IC50 values in the range of 31-143 μM. These compounds also down-regulated the mRNA expression of the MDM2 gene and up-regulated the mRNA expression of the p53 gene in HCT116 cells, as studied using qPCR analysis. This study thereby identifies several negative modulators of USP7 that can be studied further as potential anti-cancer agents.

24 days ago

Journal

TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase) • USP7 (Ubiquitin Specific Peptidase 7)

TP53 expression

24d

Cervical angiofibroma of soft tissue: A rare case report with literature review. (PubMed, Medicine (Baltimore))

Cervical angiofibroma of soft tissue is a rare tumor with a benign clinical manifestation, minimal local recurrence, and no significant metastatic potential. Treatment primarily involves local resection with a focus on achieving negative surgical margins. By presenting this case, we aim to enhance the diagnostic and differential diagnostic capabilities of pathologists in identifying uterine tumors and preventing misdiagnosis.

24 days ago

Review • Journal

ER (Estrogen receptor) • TP53 (Tumor protein P53) • PGR (Progesterone receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD163 (CD163 Molecule) • CD34 (CD34 molecule) • VIM (Vimentin) • CD68 (CD68 Molecule) • MME (Membrane Metalloendopeptidase) • STAT6 (Signal transducer and activator of transcription 6)

TP53 expression • VIM expression

24d

Analysis of the mechanism of berberine against stomach carcinoma based on network pharmacology and experimental validation. (PubMed, Transl Cancer Res)

However, in vivo experiments and clinical studies need to be further carried out. Moreover, it is necessary to study the potential negative effects of berberine thoroughly.

24 days ago

Journal

TP53 (Tumor protein P53) • IL6 (Interleukin 6) • MAPK1 (Mitogen-activated protein kinase 1) • MAPK3 (Mitogen-Activated Protein Kinase 3)

TP53 expression • AMPK expression

24d

Peimine induces apoptosis of glioblastoma cells through regulation of the PI3K/AKT signaling pathway. (PubMed, Exp Ther Med)

In conclusion, these findings suggest that peimine may limit GBM growth by regulating the PI3K/AKT signaling pathway both in vitro and in vivo. These findings may have promising clinical implications.

24 days ago

Journal • IO biomarker

TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)

BCL2 expression • TP53 expression • BAX expression

27d

The antitumour efficacy of hesperidin vs. cisplatin against non-small lung cancer cells A549 and H460 via targeting the miR-34a/PD-L1/NF-κB signalling pathway. (PubMed, Contemp Oncol (Pozn))

Our study demonstrated that hesperidin extract could significantly inhibit non-small lung cancer cell growth by induction of the apoptosis signalling pathway. Therefore, hesperidin might open novel strategies for effective and safe cancer treatment and reduce the adverse side effects of several chemotherapeutic treatments such as cisplatin.

27 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • MIR34A (MicroRNA 34a-5p)

TP53 expression

cisplatin

28d

Potential carcinogenic role of Reg IV in ulcerative colitis-associated colorectal neoplasia. (PubMed, Ecancermedicalscience)

Higher expression of Reg IV in patients with UC-dysplasia and UC-CRC versus KRAS and P53 expression in sporadic CRC, suggests a potential role of Reg IV in UC carcinogenesis pathway. This could advocate the use of Reg IV as a screening biomarker for UC-N among patients with long-standing UC as well as a promising targeted therapeutic strategy.

28 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)

TP53 expression

28d

Inulin-based nanoparticles for targeted siRNA delivery in acute kidney injury. (PubMed, J Control Release)

Selective p53 knockdown led to positive therapeutic outcomes in mice with cisplatin-induced AKI, as seen by reduced tubular cell death, renal injury, inflammation, and overall improved renal function. These findings indicate that IC is a promising new carrier for renal-targeted delivery of RNA for the treatment of AKI.

28 days ago

Journal

TP53 (Tumor protein P53) • CXCR4 (Chemokine (C-X-C motif) receptor 4)

TP53 expression • CXCR4 overexpression • CXCR4 expression

cisplatin

28d

Translational Relevance and Future Integration of the Oncopig Cancer Model in Preclinical Applications. (PubMed, Annu Rev Anim Biosci)

Its versatility has enabled the development of diverse cancer models including liver, pancreatic, lung, and bladder cancer. Serving as a clinically relevant model for human cancer, the Oncopig addresses unmet clinical needs and holds immense promise for advancing preclinical cancer research and therapeutic development.

28 days ago

Preclinical • Review • Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)

TP53 mutation • KRAS mutation • TP53 expression • KRAS expression

28d

Attenuation of aggressive tumor progression of anaplastic thyroid cancer by p53. (PubMed, Am J Cancer Res)

The discovery of the suppression of TNFα via NFκB pathway topped the pathways list, resulting in subduing the deleterious inflammatory responses caused by mutant p53. Our findings that exogenously expressed WTp53 could counter act the oncogenic actions of p53 has heightened the feasibility of using CRISPR/Cas9 genome editing to modify the p53 alleles for potential treatment of ATC.

28 days ago

Journal

TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3)

TP53 mutation • BRAF V600E • BRAF V600 • TP53 wild-type • TP53 expression

28d

IDO1-mediated kynurenine production inhibits IGFBP5 signaling to promote 5-fluorouracil-induced senescence escape and chemoresistance in colorectal cancer. (PubMed, Am J Cancer Res)

Mechanistically, the kynurenine released from IDO1-expressing CRC cells inhibited the IGFBP5/p53 signaling pathway, accounting for IDO1-mediated suppression of cell senescence and induction of chemoresistance. Collectively, these data revealed an unrecognized role of IDO1 in senescence escape and chemoresistance via releasing its catabolite kynurenine, implicating that therapeutically targeting IDO1 or IGFBP5/p53 signaling pathway holds great promise for CRC treatment.

28 days ago

Journal • IO biomarker

CCND1 (Cyclin D1) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • IGFBP5 (Insulin Like Growth Factor Binding Protein 5)

IDO1 expression • TP53 expression • IDO1 overexpression

5-fluorouracil

29d

Analysis of clinicopathological characteristics and prognostic factors in 54 metaplastic breast carcinoma patients from northwest China. (PubMed, Cytojournal)

The present study found that sentinel lymph node biopsy was feasible in appropriate patients, and that chemotherapy regimens incorporating anthracycline-class drugs did not appear to improve OS. Anti-angiogenic therapy holds promise as a potentially effective treatment approach for MBC, and the optimization of systemic treatment strategies should be a priority in the management of these patients.

29 days ago

Journal

EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • CDH1 (Cadherin 1)

TP53 mutation • EGFR expression • EGFR overexpression • EGFR positive • TP53 expression • CDH1 expression